Market Spotlight: Ischemic Stroke
|出版日期||內容資訊||英文 46 Pages
|缺血性中風:市場聚光燈 Market Spotlight: Ischemic Stroke|
|出版日期: 2020年07月31日||內容資訊: 英文 46 Pages||
Datamonitor Healthcare ，估算在2018年中在世界約發生8230萬件缺血性中風，其數預計至2027年增加到8800萬件。
This Market Spotlight report covers the Ischemic Stroke market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as licensing and acquisition deals.
Datamonitor Healthcare estimates that in 2018, there were approximately 82.3 million prevalent cases of ischemic stroke worldwide, and forecasts that number to increase to 88.0 million prevalent cases by 2027.
The approved drugs in the ischemic stroke space focus on a wide variety of targets. Most approved drugs are administered orally, with two drugs administered intravenously and one drug administered subcutaneously.
The majority of industry-sponsored drugs in active clinical development for ischemic stroke are in Phase II, with only one drug in the NDA/BLA phase.
Therapies in active clinical development for ischemic stroke focus on a wide variety of targets and include small molecules, peptides, and cell-based therapies.
High-impact upcoming events for drugs in the ischemic stroke space comprise topline Phase II trial results for Trans Sodium Crocetinate and TMS-007, topline Phase IIb trial results for ReN001, topline Phase III trial results for Cirara, and an expected PDUFA date for Brilinta.
The overall likelihood of approval of a Phase I stroke asset is 0.8%, and the average probability a drug advances from Phase III is 9.1%. Drugs, on average, take 6.8 years from Phase I to approval, compared to 9.8 years in the overall neurology space.
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for stroke have been in the early and midphases of development, with 70% of trials in Phase I-II, and 30% in Phase III-IV.
The US has a substantial lead in the number of stroke clinical trials globally. Germany leads the major European markets, while China has the top spot in Asia.
Clinical trial activity in the stroke space is dominated by completed trials. Roche has the highest number of completed clinical trials for stroke, with 21 trials.
Roche leads industry sponsors with the highest overall number of clinical trials for stroke, followed by Boehringer Ingelheim and Daiichi Sankyo.